In summary, we have utilized a genetically engineered mouse model of prostate cancer to demonstrate differential effects of treatment with sorafenib in PTEN-deficient CNCP and CRPC and provide mechanistic insights into the molecular responses. Here, PTEN is linked to Familial prostate cancer.